Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review.
Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Dreyfus I, Kakavand H, Ariannejad H, Gupta A, Madhavan MV, Van Tassell BW, Jimenez D, Monreal M, Vaduganathan M, Fanikos J, Dixon DL, Piazza G, Parikh SA, Bhatt DL, Lip GYH, Stone GW, Krumholz HM, Libby P, Goldhaber SZ, Bikdeli B. Talasaz AH, et al. Among authors: kakavand h. J Am Coll Cardiol. 2021 Oct 19;78(16):1635-1654. doi: 10.1016/j.jacc.2021.08.021. J Am Coll Cardiol. 2021. PMID: 34649702 Free PMC article. Review.
Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19).
Dixon DL, Van Tassell BW, Vecchié A, Bonaventura A, Talasaz AH, Kakavand H, D'Ascenzo F, Perciaccante A, Castagno D, Ammirati E, Biondi-Zoccai G, Stevens MP, Abbate A. Dixon DL, et al. Among authors: kakavand h. J Cardiovasc Pharmacol. 2020 May;75(5):359-367. doi: 10.1097/FJC.0000000000000836. J Cardiovasc Pharmacol. 2020. PMID: 32282502 Free PMC article. Review.
Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.
Talasaz AH, Kakavand H, Van Tassell B, Aghakouchakzadeh M, Sadeghipour P, Dunn S, Geraiely B. Talasaz AH, et al. Among authors: kakavand h. Cardiovasc Drugs Ther. 2021 Apr;35(2):249-259. doi: 10.1007/s10557-020-07037-2. Epub 2020 Jul 15. Cardiovasc Drugs Ther. 2021. PMID: 32671601 Free PMC article. Review.
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
INSPIRATION Investigators; Sadeghipour P, Talasaz AH, Rashidi F, Sharif-Kashani B, Beigmohammadi MT, Farrokhpour M, Sezavar SH, Payandemehr P, Dabbagh A, Moghadam KG, Jamalkhani S, Khalili H, Yadollahzadeh M, Riahi T, Rezaeifar P, Tahamtan O, Matin S, Abedini A, Lookzadeh S, Rahmani H, Zoghi E, Mohammadi K, Sadeghipour P, Abri H, Tabrizi S, Mousavian SM, Shahmirzaei S, Bakhshandeh H, Amin A, Rafiee F, Baghizadeh E, Mohebbi B, Parhizgar SE, Aliannejad R, Eslami V, Kashefizadeh A, Kakavand H, Hosseini SH, Shafaghi S, Ghazi SF, Najafi A, Jimenez D, Gupta A, Madhavan MV, Sethi SS, Parikh SA, Monreal M, Hadavand N, Hajighasemi A, Maleki M, Sadeghian S, Piazza G, Kirtane AJ, Van Tassell BW, Dobesh PP, Stone GW, Lip GYH, Krumholz HM, Goldhaber SZ, Bikdeli B. INSPIRATION Investigators, et al. Among authors: kakavand h. JAMA. 2021 Apr 27;325(16):1620-1630. doi: 10.1001/jama.2021.4152. JAMA. 2021. PMID: 33734299 Free PMC article. Clinical Trial.
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review.
Talasaz AH, Sadeghipour P, Kakavand H, Aghakouchakzadeh M, Kordzadeh-Kermani E, Van Tassell BW, Gheymati A, Ariannejad H, Hosseini SH, Jamalkhani S, Sholzberg M, Monreal M, Jimenez D, Piazza G, Parikh SA, Kirtane AJ, Eikelboom JW, Connors JM, Hunt BJ, Konstantinides SV, Cushman M, Weitz JI, Stone GW, Krumholz HM, Lip GYH, Goldhaber SZ, Bikdeli B. Talasaz AH, et al. Among authors: kakavand h. J Am Coll Cardiol. 2021 Apr 20;77(15):1903-1921. doi: 10.1016/j.jacc.2021.02.035. Epub 2021 Mar 16. J Am Coll Cardiol. 2021. PMID: 33741176 Free PMC article. Review.
Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial.
Bikdeli B, Talasaz AH, Rashidi F, Bakhshandeh H, Rafiee F, Rezaeifar P, Baghizadeh E, Matin S, Jamalkhani S, Tahamtan O, Sharif-Kashani B, Beigmohammadi MT, Farrokhpour M, Sezavar SH, Payandemehr P, Dabbagh A, Moghadam KG, Khalili H, Yadollahzadeh M, Riahi T, Abedini A, Lookzadeh S, Rahmani H, Zoghi E, Mohammadi K, Sadeghipour P, Abri H, Tabrizi S, Mousavian SM, Shahmirzaei S, Amin A, Mohebbi B, Parhizgar SE, Aliannejad R, Eslami V, Kashefizadeh A, Dobesh PP, Kakavand H, Hosseini SH, Shafaghi S, Ghazi SF, Najafi A, Jimenez D, Gupta A, Madhavan MV, Sethi SS, Parikh SA, Monreal M, Hadavand N, Hajighasemi A, Maleki M, Sadeghian S, Piazza G, Kirtane AJ, Van Tassell BW, Stone GW, Lip GYH, Krumholz HM, Goldhaber SZ, Sadeghipour P. Bikdeli B, et al. Among authors: kakavand h. Thromb Haemost. 2022 Jan;122(1):131-141. doi: 10.1055/a-1485-2372. Epub 2021 Jun 6. Thromb Haemost. 2022. PMID: 33865239 Clinical Trial.
Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials.
Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Kakavand H, Ariannejad H, Connors JM, Hunt BJ, Berger JS, Van Tassell BW, Middeldorp S, Piazza G, Weitz JI, Cushman M, Lip GYH, Goldhaber SZ, Bikdeli B. Talasaz AH, et al. Among authors: kakavand h. J Thromb Haemost. 2021 Dec;19(12):3080-3089. doi: 10.1111/jth.15533. Epub 2021 Sep 30. J Thromb Haemost. 2021. PMID: 34538017 Free PMC article.
Preprocedural Colchicine in Patients With Acute ST-elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Randomized Controlled Trial (PodCAST-PCI).
Hosseini SH, Talasaz AH, Alidoosti M, Tajdini M, Van Tassell BW, Etesamifard N, Kakavand H, Jalali A, Aghakouchakzadeh M, Gheymati A, Sadeghian M, Jenab Y. Hosseini SH, et al. Among authors: kakavand h. J Cardiovasc Pharmacol. 2022 Oct 1;80(4):592-599. doi: 10.1097/FJC.0000000000001317. J Cardiovasc Pharmacol. 2022. PMID: 35881907 Clinical Trial.
118 results